Back to Screener

Lifecore Biomedical, Inc. Common Stock (LFCR)

Price$5.20

Favorite Metrics

Price vs S&P 500 (26W)-25.67%
Price vs S&P 500 (4W)23.82%
Market Capitalization$199.38M

All Metrics

P/CF (Annual)27.20x
Book Value / Share (Quarterly)$0.91
P/TBV (Annual)5.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-9.91%
Cash Flow / Share (Quarterly)$0.07
Price vs S&P 500 (YTD)-36.87%
Gross Margin (TTM)31.03%
Net Profit Margin (TTM)-24.61%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)-15.13%
EPS (Annual)$-0.48
ROI (Annual)-10.18%
Gross Margin (Annual)31.37%
Net Profit Margin (5Y Avg)-40.52%
Cash / Share (Quarterly)$0.47
Revenue Growth QoQ (YoY)131.92%
ROA (Last FY)-7.74%
Revenue Growth TTM (YoY)36.20%
EBITD / Share (TTM)$-0.02
ROE (5Y Avg)-104.45%
Operating Margin (TTM)-4.21%
Cash Flow / Share (Annual)$0.10
P/B Ratio5.85x
P/B Ratio (Quarterly)9.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.82x
Net Interest Coverage (TTM)-0.13x
ROA (TTM)-18.58%
EV / EBITDA (TTM)22.35x
EPS Incl Extra (Annual)$-0.48
Current Ratio (Annual)3.49x
Quick Ratio (Quarterly)2.18x
3-Month Avg Trading Volume0.26M
52-Week Price Return-12.80%
EV / Free Cash Flow (Annual)89.25x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.87
P/S Ratio (Annual)2.64x
Asset Turnover (Annual)0.33x
52-Week High$8.98
Operating Margin (5Y Avg)-19.38%
EPS Excl Extra (Annual)$-0.48
CapEx CAGR (5Y)-31.08%
Tangible BV CAGR (5Y)-35.73%
26-Week Price Return-21.69%
Quick Ratio (Annual)2.18x
13-Week Price Return-29.12%
Total Debt / Equity (Annual)4.18x
Current Ratio (Quarterly)3.49x
Enterprise Value$324.328
Revenue / Share Growth (5Y)-19.16%
Asset Turnover (TTM)0.75x
Book Value / Share Growth (5Y)-32.61%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)-23.34%
Cash / Share (Annual)$0.47
3-Month Return Std Dev81.69%
Gross Margin (5Y Avg)29.90%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-28.49%
EBITDA Interim CAGR (5Y)-34.51%
ROE (Last FY)-52.73%
Net Interest Coverage (Annual)-0.31x
EPS Basic Excl Extra (Annual)$-0.48
P/FCF (TTM)28.96x
Receivables Turnover (TTM)5.56x
EV / Free Cash Flow (TTM)123.41x
Total Debt / Equity (Quarterly)4.18x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)3.86x
ROI (TTM)-25.21%
P/S Ratio (TTM)1.12x
Pretax Margin (5Y Avg)-29.05%
Revenue / Share (Annual)$2.02
Tangible BV / Share (Annual)$1.17
Price vs S&P 500 (52W)-42.63%
Year-to-Date Return-34.23%
5-Day Price Return13.98%
EPS Normalized (Annual)$-0.48
ROA (5Y Avg)-19.95%
Net Profit Margin (Annual)-23.78%
Month-to-Date Return44.62%
Cash Flow / Share (TTM)$-1.85
EBITD / Share (Annual)$0.09
Operating Margin (Annual)-0.97%
LT Debt / Equity (Annual)3.98x
P/CF (TTM)14.37x
ROI (5Y Avg)-29.14%
LT Debt / Equity (Quarterly)3.98x
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)8.46x
P/B Ratio (Annual)9.00x
Inventory Turnover (TTM)3.60x
Pretax Margin (TTM)-24.22%
Book Value / Share (Annual)$0.91
Price vs S&P 500 (13W)-29.80%
Beta1.13x
P/FCF (Annual)54.87x
Revenue / Share (TTM)$4.77
ROE (TTM)-105.89%
52-Week Low$3.63

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.91
3.91
3.91
4.09

Industry Peers — Pharmaceuticals(308)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
LFCRLifecore Biomedical, Inc. Common Stock
1.12x36.20%31.03%$5.20
LLYEli Lilly & Co.
13.08x44.70%83.04%27.59%$903.99
JNJJohnson & Johnson
5.94x7.87%67.95%14.90%$234.54
ABBVABBVIE INC.
6.04x8.57%71.62%-2.88%$208.99
MRKMerck & Co., Inc.
4.41x1.31%78.55%21.23%$115.46
AZNAstraZeneca PLC
5.28x8.63%81.31%21.88%$200.47
NVSNovartis AG
4.98x8.91%75.82%15.26%$149.73
NVONovo-Nordisk A/S
3.62x6.43%80.98%20.66%$40.93
ABTAbbott Laboratories
3.66x6.59%56.50%8.20%$95.47
PFEPfizer Inc.
2.47x-1.64%75.81%-3.51%$27.22
BMYBristol-Myers Squibb Co.
2.47x-0.22%72.63%$58.96

About

Lifecore Biomedical is a fully integrated CDMO providing development, manufacturing, and fill-finish services for complex sterile injectable pharmaceuticals. The company serves multiple delivery formats—syringes, vials, and cartridges—and operates two business segments: contract development and manufacturing services, and hyaluronic acid manufacturing.